RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.…
RxSight, Inc. to Present at the Piper Sandler Healthcare Conference
RxSight (NASDAQ: RXST) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 461 employees.
The shares were at 4.470 USD on 20 November 2026, down 48.1% over 52 weeks. Its 52-week range is 4.110 USD to 13.22 USD: the price is 66.2% below the high and 8.8% above the low.
Its market capitalisation is 187.42M USD.
RxSight reports return on equity of -14.1%, an operating margin of -50.4% and revenue down 19.0% year over year.
It holds more cash than debt, a net cash position of 244.36M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 8 analysts cover the stock, with an average rating of Hold; their mean price target of 6.100 USD is 36.5% above the current price. The next earnings report is expected on 24 February 2027.